2026-04-13T14:23:45Zhttps://recercat.cat/oai/request
oai:recercat.cat:10230/604222025-12-13T21:22:47Zcom_2072_6col_2072_452952
RECERCAT author van Eijck, Casper W. F. author Real, Francisco X. author Malats i Riera, Núria author Vadgama, Disha author van den Bosch, Thierry P. P. author Doukas, Michail author van Eijck, Casper H. J. author Mustafa, Dana A. M. author Dutch Pancreatic Cancer Group (DPCG) 2024-06-11T06:13:30Z2024-06-11T06:13:30Z2024 This study underscores GATA6's role in distinguishing classical and basal-like pancreatic ductal adenocarcinoma (PDAC) phenotypes. Retrospective studies associate GATA6 immunohistochemistry (IHC) expression with survival outcomes, warranting prospective validation. In a prospective treatment-naive cohort of patients with resected PDAC, GATA6 IHC proves a prognostic discriminator, associating high GATA6 expression with extended survival and the classical PDAC phenotype. However, GATA6's prognostic significance is numerically lower after gemcitabine-based neoadjuvant chemoradiotherapy compared to its significance in patients treated with upfront surgery. Furthermore, GATA6 is implicated in immunomodulation, although a comprehensive investigation of its immunological role is lacking. Treatment-naive PDAC tumors with varying GATA6 expression yield distinct immunological landscapes. Tumors highly expressing GATA6 show reduced infiltration of immunosuppressive regulatory T cells and M2 macrophages but increased infiltration of immune-stimulating, antigen-presenting, and activated T cells. Our findings caution against solely relying on GATA6 for molecular subtyping in clinical trials and open avenues for exploring immune-based combination therapies.The laboratory of C.H.J.v.E. receives financial support from the Survival with Pancreatic Cancer Foundation (www.supportcasper.nl) (grant number OVIT17-06). The laboratory of F.X.R. receives financial support from Ministerio de Ciencia, Innovación y Universidades (grant number PID2020-119533GB-I00). The CNIO receives support from the Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa (grant number SEV-2015-0510). © 2024 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess GATA6 PDAC Immune profiling Pancreatic ductal adenocarcinoma Randomized controlled trial Tumor microenvironment GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion